Literature DB >> 293683

Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene.

B Chesebro, K Wehrly, D Doig, J Nishio.   

Abstract

The Rfv-3 gene was found to influence the level of Friend leukemia virus production in spleens of leukemic mice later than 30 days after virus inoculation. Rfv-3r/s mice [(B10.A X A)F1 and (B10.A X A.BY)F1] had decreased spleen virus levels 30-90 days after virus inoculation compared to Rfv-3s/s mice [A.BY, A, BALB.B, and (BALB/c X A)F1)]. In (B10.A X A)F1 X A backcross mice the spleen virus titer segregated with the level of viremia. The Rfv-3 gene appeared to act by controlling anti-Friend virus antibody production. The interaction of antiviral antibody with infected cells led to a decrease in release of infectious virus by late leukemic spleen cells in Rfv-3r/s mice to 1/300th that in Rfv-3s/s mice. This decrease in virus release appeared to be due to interference with the virus budding process due to antibody-mediated modulation of virus-induced cell surface antigens.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 293683      PMCID: PMC411735          DOI: 10.1073/pnas.76.11.5784

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Pathogenesis of mouse leukemia caused by Friend virus.

Authors:  D METCALF; J FURTH; R F BUFFETT
Journal:  Cancer Res       Date:  1959-01       Impact factor: 12.701

2.  Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes.

Authors:  O N Witte; A Tsukamoto-Adey; I L Weissman
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

3.  Antigenic shift of visna virus in persistently infected sheep.

Authors:  O Narayan; D E Griffin; J Chase
Journal:  Science       Date:  1977-07-22       Impact factor: 47.728

4.  Inhibition of bovine leukemia virus release by antiviral antibodies.

Authors:  D M Driscoll; M Onuma; C Olson
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

5.  Murine leukemia virus infectious centers are dependent on the rate of virus production by infected cells.

Authors:  B Chesebro; K Wehrly; K Watson; K Chesebro
Journal:  Virology       Date:  1978-01       Impact factor: 3.616

6.  Antibody-induced modulation and shedding of mammary tumor virus antigens on the surfaces of GR ascites leukemia cells as compared with normal antigens.

Authors:  J Calafat; J Hilgers; W J Van Bitterswijk; M Verbeet; P C Hageman
Journal:  J Natl Cancer Inst       Date:  1976-05       Impact factor: 13.506

7.  Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines.

Authors:  B Chesebro; K Wehrly; K Chesebro; J Portis
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

8.  Viral proteins expressed on the surface of murine leukemia cells.

Authors:  J Ledbetter; R C Nowinski; S Emery
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

9.  Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia.

Authors:  C FRIEND
Journal:  J Exp Med       Date:  1957-04-01       Impact factor: 14.307

View more
  24 in total

1.  Antibodies to cell surface proteins redirect intracellular trafficking pathways.

Authors:  Christine A St Pierre; Deborah Leonard; Silvia Corvera; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  Exp Mol Pathol       Date:  2011-07-23       Impact factor: 3.362

2.  Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Authors:  A Leemans; M De Schryver; W Van der Gucht; A Heykers; I Pintelon; A L Hotard; M L Moore; J A Melero; J S McLellan; B S Graham; L Broadbent; U F Power; G Caljon; P Cos; L Maes; P Delputte
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response.

Authors:  Kalani Halemano; Bradley S Barrett; Karl J Heilman; Thomas E Morrison; Mario L Santiago
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

4.  Differing T-cell requirements for recombinant retrovirus vaccines.

Authors:  K J Hasenkrug; D M Brooks; J Nishio; B Chesebro
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

Review 5.  Role of the major histocompatibility complex in resistance to viral leukemia; its effect on the preleukemic stage of leukemogenesis.

Authors:  P Lonai; E Katz; N Haran-Ghera
Journal:  Springer Semin Immunopathol       Date:  1982

6.  Frequent hereditable shutdown of murine retrovirus gene expression in murine cell lines.

Authors:  R K Bestwick; C A Machida; E Polonoff; D Kabat
Journal:  Mol Cell Biol       Date:  1984-05       Impact factor: 4.272

7.  Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15.

Authors:  H J Super; K J Hasenkrug; S Simmons; D M Brooks; R Konzek; K D Sarge; R I Morimoto; N A Jenkins; D J Gilbert; N G Copeland; W Frankel; B Chesebro
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

8.  Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor.

Authors:  Mario L Santiago; Diana S Smith; Bradley S Barrett; Mauricio Montano; Robert L Benitez; Roberta Pelanda; Kim J Hasenkrug; Warner C Greene
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

9.  Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia.

Authors:  L L Perry; M Miyazawa; K Hasenkrug; K Wehrly; C S David; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice.

Authors:  M N Robertson; G J Spangrude; K Hasenkrug; L Perry; J Nishio; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.